Startseite Kongressberichte 2020 ESMO VIRTUAL 2020 Gynaecological Cancers Proffered Paper 1 - Gynaecological cancers

Proffered Paper 1 - Gynaecological cancers

LINK to Proffered Paper 1 - Gynaecological cancers

LINK to STREAM (needs an ESMO registration)

LBA28 - A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial

The abstract concludes: The L + palbociclib combination demonstrated clinically meaningful improvement in PFS with manageable toxicity, meriting phase III investigation.


806O - Radical hysterectomy in cervical cancer patients with intraoperatively detected positive lymph node: ABRAX multicentric retrospective cohort study (ENGOT-Cx3/CEEGOG CX2)

The abstract concludes: ABRAX trial revealed that completion of radical hysterectomy in patients with intraoperative detection of positive lymph node does not improve the survival; recurrence risk is not decreased irrespective of tumour size or tumour type. Therefore, if pelvic LN involvement is diagnosed at surgery, abandonment of planned uterine procedure should be considered and the patient should be referred to definitive chemoradiation.


LBA29 - Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)

The abstract concludes: This is the first study to demonstrate the efficacy and safety of niraparib in Chinese patients with PSROC. ISD of niraparib is effective and safe and should be considered a standard clinical practice in this patient population.




LBA30 - INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

The abstract concludes: This study did not meet its primary endpoint of improving OS with the TP regimen followed by platinum over CP regimen. However, as TP reached similar OS, it can still be considered in pts who need a longer recovery time from platinum specific toxicities.